Drug treatment effects on disease progression

被引:113
作者
Chan, PLS [1 ]
Holford, NHG [1 ]
机构
[1] Univ Auckland, Sch Med, Div Pharmacol & Clin Pharmacol, Auckland 1030, New Zealand
关键词
disease progress models; symptomatic; protective; Alzheimer's; Parkinson's; osteoporosis;
D O I
10.1146/annurev.pharmtox.41.1.625
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Degenerative diseases are characterized by a worsening of disease status over time. The rate of deterioration is determined by the natural rate of progression of the disease and by the effect of drug treatments. A goal of drug treatment is to slow disease progression. Drug treatments can be categorized as symptomatic or protective. Symptomatic treatments do not affect the rate of disease progression whereas protective treatments have the ability to slow disease progression down. Many current methods for describing disease progression have two common drawbacks: a linear relationship between time and disease status is assumed, and within- and between-subject variability is ignored. Disease progress models combined with pharmacokinetic-pharmacodynamic models and hierarchical random effects statistical models provide insights into understanding the time course and management of degenerative disease.
引用
收藏
页码:625 / 659
页数:35
相关论文
共 148 条
  • [91] THE CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMERS-DISEASE (CERAD) .4. RATES OF COGNITIVE CHANGE IN THE LONGITUDINAL ASSESSMENT OF PROBABLE ALZHEIMERS-DISEASE
    MORRIS, JC
    EDLAND, S
    CLARK, C
    GALASKO, D
    KOSS, E
    MOHS, R
    VANBELLE, G
    FILLENBAUM, G
    HEYMAN, A
    [J]. NEUROLOGY, 1993, 43 (12) : 2457 - 2465
  • [92] MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57
  • [93] Morrish PK, 1996, ADV NEUROL, V69, P427
  • [94] Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F] dopa PET
    Morrish, PK
    Rakshi, JS
    Bailey, DL
    Sawle, GV
    Brooks, DJ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) : 314 - 319
  • [95] An [F-18]dopa-PET and clinical study of the rate of progression in Parkinson's disease
    Morrish, PK
    Sawle, GV
    Brooks, DJ
    [J]. BRAIN, 1996, 119 : 585 - 591
  • [96] SELEGILINE AS INITIAL TREATMENT IN DENOVO PARKINSONIAN-PATIENTS
    MYLLYLA, VV
    SOTANIEMI, KA
    VUORINEN, JA
    HEINONEN, EH
    [J]. NEUROLOGY, 1992, 42 (02) : 339 - 343
  • [97] Bone loss, physical activity, and weight change in elderly women: The Dubbo Osteoporosis Epidemiology Study
    Nguyen, TV
    Sambrook, PN
    Eisman, JA
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (09) : 1458 - 1467
  • [98] MAGNITUDE AND PATTERN OF SKELETAL RESPONSE TO LONG-TERM CONTINUOUS AND CYCLIC SEQUENTIAL OESTROGEN/PROGESTIN TREATMENT
    NIELSEN, SP
    BARENHOLDT, O
    HERMANSEN, F
    MUNKJENSEN, N
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1994, 101 (04): : 319 - 324
  • [99] The response to levodopa in Parkinson's disease: Imposing pharmacological law and order
    Nutt, JG
    Holford, NHG
    [J]. ANNALS OF NEUROLOGY, 1996, 39 (05) : 561 - 573
  • [100] EFFECT OF LONG-TERM THERAPY ON THE PHARMACODYNAMICS OF LEVODOPA - RELATION TO ON-OFF PHENOMENON
    NUTT, JG
    WOODWARD, WR
    CARTER, JH
    GANCHER, ST
    [J]. ARCHIVES OF NEUROLOGY, 1992, 49 (11) : 1123 - 1130